TABLE 1.
Baseline characteristics of the study population at baseline
| Tac (n = 79) | CyA-ME (n = 77) | |
|---|---|---|
| Median age (IQR), y | 1.96 (0.83–6.62) | 1.06 (0.69–4.72) |
| Male, n (%) | 41 (51.8) | 42 (54.5) |
| EBV IgG negative, n (%)a | 30 (37.9) | 31 (40.2) |
| Baseline median eGFR | 122 | 109.6 |
| Primary diagnosis, n (%) | ||
| Biliary atresia | 47 (59.4) | 40 (51.9) |
| Cirrhosis | 3 (3.8) | 7 (9.1) |
| Alagille’s syndrome | 6 (7.6) | 6 (7.8) |
| Metabolic syndrome | 1 (1.3) | 1 (1.3) |
| Byler’s disease | 8 (10.1) | 4 (5.2) |
| Other, n(%) | 9 (11.4) | 13 (16.8) |
| Deceased graft, n (%) | 66 (83.5) | 63 (81.8) |
| Living-related graft, n (%) | 13 (16.4) | 14 (18.2) |
| Reduced/split liver graft, n (%) | 58 (73.4) | 62 (80.5) |
Comparisons between the Tac and CyA-ME cohorts by Mann-Whitney U analysis reported P value >0.05. eGFR units are (mL/min/1.73 m2).
aData not recorded for 14 patients randomized to Tac and 17 patients on CyA-ME.
CyA-ME, cyclosporine A microemulsion; EBV, Epstein-Barr virus; eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; IQR, interquartile range; Tac, tacrolimus.